Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9871631rdf:typepubmed:Citationlld:pubmed
pubmed-article:9871631lifeskim:mentionsumls-concept:C0017890lld:lifeskim
pubmed-article:9871631lifeskim:mentionsumls-concept:C0051318lld:lifeskim
pubmed-article:9871631lifeskim:mentionsumls-concept:C0079883lld:lifeskim
pubmed-article:9871631lifeskim:mentionsumls-concept:C0243076lld:lifeskim
pubmed-article:9871631lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:9871631lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:9871631lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:9871631pubmed:issue1lld:pubmed
pubmed-article:9871631pubmed:dateCreated1999-1-26lld:pubmed
pubmed-article:9871631pubmed:abstractTextPotent antagonists at the glycine-binding site of NMDA receptors, as well as dual antagonists acting also at AMPA receptors have been identified in a series of 5-arylaminomethylquinoxaline-2,3-diones. A study of the structure-activity relationship of these compounds is reported here.lld:pubmed
pubmed-article:9871631pubmed:languageenglld:pubmed
pubmed-article:9871631pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9871631pubmed:citationSubsetIMlld:pubmed
pubmed-article:9871631pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9871631pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9871631pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9871631pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9871631pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9871631pubmed:statusMEDLINElld:pubmed
pubmed-article:9871631pubmed:monthJanlld:pubmed
pubmed-article:9871631pubmed:issn0960-894Xlld:pubmed
pubmed-article:9871631pubmed:authorpubmed-author:BischoffSSlld:pubmed
pubmed-article:9871631pubmed:authorpubmed-author:BiollazMMlld:pubmed
pubmed-article:9871631pubmed:authorpubmed-author:OfnerSSlld:pubmed
pubmed-article:9871631pubmed:authorpubmed-author:AllgeierHHlld:pubmed
pubmed-article:9871631pubmed:authorpubmed-author:VeenstraS JSJlld:pubmed
pubmed-article:9871631pubmed:authorpubmed-author:AcklinPPlld:pubmed
pubmed-article:9871631pubmed:authorpubmed-author:AubersonY PYPlld:pubmed
pubmed-article:9871631pubmed:issnTypePrintlld:pubmed
pubmed-article:9871631pubmed:day6lld:pubmed
pubmed-article:9871631pubmed:volume8lld:pubmed
pubmed-article:9871631pubmed:ownerNLMlld:pubmed
pubmed-article:9871631pubmed:authorsCompleteYlld:pubmed
pubmed-article:9871631pubmed:pagination71-4lld:pubmed
pubmed-article:9871631pubmed:dateRevised2000-12-18lld:pubmed
pubmed-article:9871631pubmed:meshHeadingpubmed-meshheading:9871631-...lld:pubmed
pubmed-article:9871631pubmed:meshHeadingpubmed-meshheading:9871631-...lld:pubmed
pubmed-article:9871631pubmed:meshHeadingpubmed-meshheading:9871631-...lld:pubmed
pubmed-article:9871631pubmed:meshHeadingpubmed-meshheading:9871631-...lld:pubmed
pubmed-article:9871631pubmed:meshHeadingpubmed-meshheading:9871631-...lld:pubmed
pubmed-article:9871631pubmed:meshHeadingpubmed-meshheading:9871631-...lld:pubmed
pubmed-article:9871631pubmed:year1998lld:pubmed
pubmed-article:9871631pubmed:articleTitle5-Aminomethylquinoxaline-2,3-diones. Part II: N-aryl derivatives as novel NMDA/glycine and AMPA antagonists.lld:pubmed
pubmed-article:9871631pubmed:affiliationNovartis Pharma AG, Basel, Switzerland. yves.auberson@pharma.novartis.comlld:pubmed
pubmed-article:9871631pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:9871631lld:chembl